ReviewCurrent treatment options in oncology2022
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity.
Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Advancing immune checkpoint inhibitor rechallenge: key insights into efficacy, safety, and personalized strategies in advanced solid tumors.Frontiers in oncology · 2026Pooled it
- Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Microbial engraftment and immune regulation during fecal microbiota transplantation and immune checkpoint inhibitor therapy.Nature communications · 2026Review
- Article
- A comprehensive analysis and visualization of immune-related adverse events in lung cancer immunotherapy a bibliometric study.Discover oncology · 2026Review
- Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.Frontiers in endocrinology · 2026Review
- Association of anti-PD-(L)1 treatment duration to efficacy in advanced solid tumors: a single center retrospective study.Annals of medicine · 2025Article
- Trends in immunotherapy for oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report.Translational lung cancer research · 2025Article
- Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management.Journal of cardiovascular development and disease · 2025Review
- Immunotherapy rechallenge after significant toxicity - can it be done successfully?Immunotherapy · 2025Article
- Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge-A Systematic Review.Cancers · 2023Review
- Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events.Clinical kidney journal · 2023Review
- Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer.Frontiers in immunology · 2023Article
- Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review.Frontiers in immunology · 2023Review
- Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementImmune checkpoint inhibitors (ICIs) have become an essential part of treatment for many cancer types. These monoclonal antibodies remove a critical negative regulatory signal that allows the immune system to recognize and destroy malignant cells that were previously undetectable. Unfortunately, their use has ushered in a whole new form of drug toxicity whereby the immune system attacks normal tissues in the body, referred to hereafter as immune-related adverse events (irAEs). irAEs are common and can result in treatment discontinuation, hospitalization, and death. When alternative modes of treatment are limited, or considered less efficacious, there may be a desire to resume treatment with ICIs after an irAE. Rechallenge with ICIs carries with it a heightened risk of subsequent toxicity, but with careful consideration and appropriate patient selection, this can be considered a reasonable approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.